Hainsworth J D, Greco F A
Division of Oncology, Vanderbilt University, School of Medicine.
Oncology (Williston Park). 1988 Jul;2(7):43-9, 52-4.
Patients with carcinoma of unknown primary site are heterogeneous with respect to tumor biology, clinical characteristics, and response to therapy. These patients should no longer be considered uniformly "untreatable"; careful evaluation can identify treatable subsets. The initial light microscopic findings should be used to categorize patients into one of three groups: Well-differentiated adenocarcinoma, poorly differentiated carcinoma (or adenocarcinoma), and squamous carcinoma. Subsequent evaluation and treatment differ for these three groups. Poorly differentiated carcinomas are often responsive to cisplatin-based chemotherapy; effective systemic treatments are also available for some subsets of patients with adenocarcinoma. Surgery and/or radiotherapy is often beneficial for patients with squamous carcinoma, especially those who have isolated cervical lymphadenopathy.
原发部位不明的癌患者在肿瘤生物学、临床特征及对治疗的反应方面存在异质性。这些患者不应再被一概而论地视为“无法治疗”;仔细评估可识别出可治疗的亚组。最初的光镜检查结果应用于将患者分为三组之一:高分化腺癌、低分化癌(或腺癌)和鳞癌。这三组患者的后续评估和治疗有所不同。低分化癌通常对基于顺铂的化疗有反应;对于某些腺癌患者亚组也有有效的全身治疗方法。手术和/或放疗对鳞癌患者通常有益,尤其是那些有孤立性颈部淋巴结病的患者。